Cargando…
Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
BACKGROUND: The optimal way to home-monitor patients with inflammatory bowel disease (IBD) for disease progression or relapse remains to be found. AIM: To determine whether an electronic health (eHealth) screening procedure for disease activity in IBD should be implemented in clinical practice, sche...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824278/ https://www.ncbi.nlm.nih.gov/pubmed/31686770 http://dx.doi.org/10.3748/wjg.v25.i40.6158 |
_version_ | 1783464709187436544 |
---|---|
author | Ankersen, Dorit Vedel Weimers, Petra Marker, Dorte Bennedsen, Mette Saboori, Sanaz Paridaens, Kristine Burisch, Johan Munkholm, Pia |
author_facet | Ankersen, Dorit Vedel Weimers, Petra Marker, Dorte Bennedsen, Mette Saboori, Sanaz Paridaens, Kristine Burisch, Johan Munkholm, Pia |
author_sort | Ankersen, Dorit Vedel |
collection | PubMed |
description | BACKGROUND: The optimal way to home-monitor patients with inflammatory bowel disease (IBD) for disease progression or relapse remains to be found. AIM: To determine whether an electronic health (eHealth) screening procedure for disease activity in IBD should be implemented in clinical practice, scheduled every third month (3M) or according to patient own decision, on demand (OD). METHODS: Adult IBD patients were consecutively randomized to 1-year open-label eHealth interventions (3M vs OD). Both intervention arms were screening for disease activity, quality of life and fatigue and were measuring medical compliance with the constant care web-application according to the screening interventions OD or 3M. Disease activity was assessed using home measured fecal calprotectin (FC) and a disease activity score. RESULTS: In total, 102 patients were randomized (n = 52/50 3M/OD) at baseline, and 88 patients completed the 1-year study (n = 43 3M; n = 45 OD). No difference in the two screening procedures could be found regarding medical compliance (P = 0.58), fatigue (P = 0.86), quality of life (P = 0.17), mean time spent in remission (P > 0.32), overall FC relapse rates (P = 0.49), FC disease courses (P = 0.61), FC time to a severe relapse (P = 0.69) and remission (P = 0.88) during 1 year. Median (interquartile range) numbers of FC home-monitoring test-kits used per patient were significantly different, 3M: 6.0 (5.0-8.0) and OD: 4.0 (2.0-9.0), P = 0.04. CONCLUSION: The two eHealth screening procedures are equally good in capturing a relapse and bringing about remission. However, the OD group used fewer FC home test-kits per patient. Individualized screening procedures can be recommended for adult IBD patients in clinical web-practice. |
format | Online Article Text |
id | pubmed-6824278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-68242782019-11-04 Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial Ankersen, Dorit Vedel Weimers, Petra Marker, Dorte Bennedsen, Mette Saboori, Sanaz Paridaens, Kristine Burisch, Johan Munkholm, Pia World J Gastroenterol Randomized Clinical Trial BACKGROUND: The optimal way to home-monitor patients with inflammatory bowel disease (IBD) for disease progression or relapse remains to be found. AIM: To determine whether an electronic health (eHealth) screening procedure for disease activity in IBD should be implemented in clinical practice, scheduled every third month (3M) or according to patient own decision, on demand (OD). METHODS: Adult IBD patients were consecutively randomized to 1-year open-label eHealth interventions (3M vs OD). Both intervention arms were screening for disease activity, quality of life and fatigue and were measuring medical compliance with the constant care web-application according to the screening interventions OD or 3M. Disease activity was assessed using home measured fecal calprotectin (FC) and a disease activity score. RESULTS: In total, 102 patients were randomized (n = 52/50 3M/OD) at baseline, and 88 patients completed the 1-year study (n = 43 3M; n = 45 OD). No difference in the two screening procedures could be found regarding medical compliance (P = 0.58), fatigue (P = 0.86), quality of life (P = 0.17), mean time spent in remission (P > 0.32), overall FC relapse rates (P = 0.49), FC disease courses (P = 0.61), FC time to a severe relapse (P = 0.69) and remission (P = 0.88) during 1 year. Median (interquartile range) numbers of FC home-monitoring test-kits used per patient were significantly different, 3M: 6.0 (5.0-8.0) and OD: 4.0 (2.0-9.0), P = 0.04. CONCLUSION: The two eHealth screening procedures are equally good in capturing a relapse and bringing about remission. However, the OD group used fewer FC home test-kits per patient. Individualized screening procedures can be recommended for adult IBD patients in clinical web-practice. Baishideng Publishing Group Inc 2019-10-28 2019-10-28 /pmc/articles/PMC6824278/ /pubmed/31686770 http://dx.doi.org/10.3748/wjg.v25.i40.6158 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Randomized Clinical Trial Ankersen, Dorit Vedel Weimers, Petra Marker, Dorte Bennedsen, Mette Saboori, Sanaz Paridaens, Kristine Burisch, Johan Munkholm, Pia Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial |
title | Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial |
title_full | Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial |
title_fullStr | Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial |
title_full_unstemmed | Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial |
title_short | Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial |
title_sort | individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial |
topic | Randomized Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824278/ https://www.ncbi.nlm.nih.gov/pubmed/31686770 http://dx.doi.org/10.3748/wjg.v25.i40.6158 |
work_keys_str_mv | AT ankersendoritvedel individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial AT weimerspetra individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial AT markerdorte individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial AT bennedsenmette individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial AT saboorisanaz individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial AT paridaenskristine individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial AT burischjohan individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial AT munkholmpia individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial |